Nussdorf Glenn H 的 Form 4 申報
Organogenesis Holdings Inc.（ORGO），2021/11/22 申報
- 申報編號
- 0001062993-21-011406
- 申報時間
- 2021/11/22 20:39 ET
- 交易日
- 2021/11/18
- 申報延遲
- 4 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 1 筆非衍生性交易。公開市場買進合計 $24.8 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Nussdorf Glenn HCIK 0001244191 | 董事、持股 10% 以上大股東 |
| Ades Alan A.CIK 0001757286 | 董事、持股 10% 以上大股東 |
| Erani AlbertCIK 0001074084 | 持股 10% 以上大股東 |
| Dennis Erani 2012 Issue Trust dated 12/20/12CIK 0001757455 | 持股 10% 以上大股東 |
| Alan Ades 2014 GRATCIK 0001757567 | 持股 10% 以上大股東 |
| Organo Investors LLCCIK 0001757573 | 持股 10% 以上大股東 |
| Organo PFG LLCCIK 0001757580 | 持股 10% 以上大股東 |
| Albert Erani Family Trust dated 12/29/2012CIK 0001760663 | 持股 10% 以上大股東 |
| Erani DennisCIK 0001760685 | 持股 10% 以上大股東 |
| Wisdom StarrCIK 0001760694 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/11/18 | Class A Common Stock | P買進取得 | +25,000 | $9.93F2 | +$248,250 | 59,448,027 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $9.89 to $9.95, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
備註
Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, referred to collectively as the "Group", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Group with respect to four directors of the Issuer. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 4 No. 1 of 2 filed for the Group.